Farr Nezhat, MD
Gynecologic Oncology · New York, NYNPI 1700837432
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,350 of the $40,979 with a category attached, or 66.7%. AbbVie accounts for 78.2% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $31,943 and has fallen 99.8% since, to $54 in 2025. Among gynecologic oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 94 payments — averaging $435.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$32K
- Intuitive Surgical$5K
- Aspira Women's Health Inc$2K
- Momentis Surgical Inc.$1K
- Gynesonics, Inc.$392
- Teleflex LLC$212
- plus $1K from 11 others
What the payments were for
- Speaking & faculty fees$27,35067%
- Travel & lodging$6,12015%
- Food & beverage$3,4788%
- Education$4,03110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 55 | $32,029 |
| Intuitive Surgical | 4 | $4,699 |
| Aspira Women's Health Inc | 2 | $1,561 |
| Momentis Surgical Inc. | 5 | $1,072 |
| Gynesonics, Inc. | 2 | $392 |
| Teleflex LLC | 3 | $212 |
| Eisai Inc. | 2 | $161 |
| Davol Inc. | 1 | $155 |
| Sumitomo Pharma America, Inc. | 3 | $152 |
| Myovant Sciences Inc. | 8 | $121 |
| KARL Storz Endoscopy-america | 2 | $118 |
| Mimedx Group, Inc. | 1 | $118 |
| GSK | 2 | $62 |
| AstraZeneca | 1 | $55 |
| Medtronic | 1 | $31 |
| Provepharm Inc. | 1 | $23 |
| Coopersurgical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,979 in reported general payments places this provider in the 90th percentile of 154 gynecologic oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 41 | $5,163 |
| Gabapentin | 11 | $7 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in New York
- Bhavana PothuriNew York$366K
- Mario LeitaoNew York$116K
- Konstantin ZakashanskyNew York$93K
- Evelyn CantilloNew York$79K
- Kristen ZeligsNew York$38K
- Nimesh NagarshethNew York$33K
- Jeff LinNew York$30K
- Valentin KolevNew York$23K
- Jason WrightNew York$19K
- Kevin HolcombNew York$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.